Human Sialylated Lewis a / CA 19-9

Mouse

Human (tested or 100% immunogen sequence identity)

IgM,k Monoclonal

121SLE

Unconjugated

PEG purified

Unmodified. Also available Ready-to-Use, Azide-free, BSA-free.

Precipitin lines obtained after immuno-diffusion using mAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le) were used as the immunogen for the CA19-9 antibody.

Human CA 19-9

• IHC
• IHC - Paraffin (0.5 - 1 µg/ml)
• Immunofluorescence (0.5 - 1 µg/ml)
• Flow Cytometry (0.5 - 1 µg/10E6 cells)

CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This mAb is excellent for staining of formalin-fixed, paraffin-embedded tissues. Optimal dilution of the CA19-9 antibody should be determined by the researcher. No special pretreatment is required for the immunohistochemical staining of formalin-fixed, paraffin-embedded tissues.

1X PBS, 0.1 mg/ml BSA, 0.05% sodium azide

Store at 2°C to 8°C.

For research use only. Intended for use by laboratory professionals.

This antibody carries the LSBio 100% Guarantee.